Abstract: This invention relates to novel compounds F-18 radio-labeled amino-alcohols suitable for labeling or already labeled by 18F methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

Abstract: The present invention relates to a polyamine-substituted ligand for the preparation of a contrast agent derived from a chelating molecule selected from the group consisting of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and diethylentriamine-pentaacetic acid (DTPA), wherein at least one of the carboxylic groups of the chelating molecule is reacted with an amine of formula HNR1R2 to form an amide bond, wherein R1, R2 are independently selected from the group consisting of H; (CH2)n—NR3R4; and R5; R3, R4 are independently selected from the group consisting of H; (CH2)m—NR6R7; and (CH2)m-1—CH3; R6, R7 are independently selected from the group consisting of H; and (CH2)o-1—CH3; n, m, o are independently 2, 3, or 4; R5 is of formula and optionally at least one of the carboxylic groups of the chelating molecule is further reacted with a monoalkylamine having 1 to 18 carbon atoms to form an amide bond; provided that at least one of R1, R2 is other than H.

Abstract: What is described are compounds wherein R represents Br, I or R1—SO3, where R1 is an unsubstituted or substituted C1–C5-alkyl group, or an unsubstituted or substituted phenyl group; X is O or NR?, where R? is a usual protective group for N; and R? represents hydrogen, a halogen, such as F, Cl, and Br, a substituted or unsubstituted C1–C7-alkyl group, such as methyl and ethyl, a substituted or unsubstituted C2–C7-alkenyl group, or a substituted or unsubstituted C2–C7-alkynyl group.

Abstract: A method for fabricating an integrated semiconductor circuit having at least two different wiring forms realized in a same metallization plane includes drawing each of the different wiring forms on respectively different layer types. In this manner, the at least two different wiring forms can be individually and jointly analyzed.

Abstract: What is described are compounds wherein R represents Br, I or R1—SO3, where R1 is an unsubstituted or substituted C1-C5-alkyl group, or an unsubstituted or substituted phenyl group; X is O or NR?, where R? is a usual protective group for N; and R? represents hydrogen, a halogen, such as F, Cl, and Br, a substituted or unsubstituted C1-C7-alkyl group, such as methyl and ethyl, a substituted or unsubstituted C2-C7-alkenyl group, or a substituted or unsubstituted C2-C7-alkynyl group.

Abstract: The application relates to compounds that are suitable as labelable precursors for synthesis of 3?-[18F]fluoro-3?-deoxythymidine and that have formula (1), in which R denotes triphenylmethyl, triphenylmethyl substituted in the phenyl group, trialkylmethyl, triphenylsilyl, triphenylsilyl substituted in the phenyl group, or trialkylsilyl, R? denotes R1—SO2, where R1 is an unsubstituted or substituted C1 to C5 alkyl or an unsubstituted or substituted phenyl, and R? denotes C2 to C10 alkyloxycarbonyl, with the exception of 3-N-Boc-1-(3-O-nosyl-5-O-trityl-2-deoxy-?-D-lyxofuranosy The application also relates to a method for preparation of these compounds and to the use of the same for synthesis of 3?-[18F]fluoro-3?-deoxythymidine.

Abstract: The application relates to compounds that are suitable as labelable precursors for synthesis of 3′-[18F]fluoro-3′-deoxythymidine and that have formula (1), 1

Abstract: A method for fabricating an integrated semiconductor circuit having at least two different wiring forms realized in a same metallization plane includes drawing each of the different wiring forms on respectively different layer types. In this manner, the at least two different wiring forms can be individually and jointly analyzed.

Abstract: The present invention relates to an oligonucleotide conjugate, comprising: (a) an oligonucleotide at least part of whose sequence is complementary to an intracellular nucleic acid sequence; and (b) a somatostatin analog. The present invention also relates to a medicament containing this oligonucleotide conjugate, preferably for treating tumors in which the somatostatin receptor (SSTR) is overexpressed.